Nick Paul Taylor
Nick Paul Taylor follows the money and risk in drug development, turning biotech news into clear stories about how clinical events and corporate decisions affect the business of pharmaceuticals. At Fierce Biotech he covers the biopharma business, with a focus on late-stage data, competitive dynamics and how investors and executives respond when experimental drugs succeed or fall short.
Biotech business framed through clinical outcomes
Taylor’s coverage starts from the science but is driven by what it means for the company’s strategy. He writes about phase 2 and phase 3 readouts in terms of their impact on pipelines, partnerships and commercial prospects rather than only the underlying biology. In his reporting on Regeneron’s melanoma program failing to beat Keytruda in a phase 3 trial, he moves quickly from the headline result to what it means for Regeneron’s position in immuno-oncology and its effort to challenge an entrenched standard of care.
He routinely explains trial design, endpoints and patient populations just far enough for an industry audience to follow the stakes. Technical terms such as phase design, primary endpoint and standard-of-care comparator sit alongside plain language about winners, losers and missed opportunities. That approach lets him show how a single dataset can change the commercial trajectory of a program, a franchise or a therapeutic area.
Setbacks are a recurring lens. Rather than treating a negative or inconclusive result as a dead end, he unpacks the implications for future indications, follow-on assets and rival companies in the same space. The emphasis is on portfolio impact, reprioritisation and the questions boards and investors will be asking after the news lands.
Analyst insight and competitive context
Taylor frequently uses analyst reaction as a spine for his stories, reflecting the market-facing nature of his beat. In the Regeneron melanoma piece, the “shaking heads” response from analysts is not a throwaway quote but a signal of how the investment community is recalibrating its view of the asset and its chances against Keytruda. He elevates those reactions to the headline level when they capture the shift in sentiment or crystallise technical doubts in plain language.
Competitive context is central to how he frames drug news. A trial result is rarely presented in isolation; it is read against benchmark products, near-term rivals and combination strategies that matter to oncologists and payers. Keytruda’s established role in melanoma, for example, becomes the yardstick by which Regeneron’s effort is judged, and Taylor makes clear what failing to surpass that benchmark means for future uptake and differentiation.
Across his biopharma business coverage he tends to foreground questions such as: Will this result justify further investment? How does it change the negotiation power in current or future partnerships? What does it signal for similar mechanisms under development elsewhere? Analyst notes, price moves and management commentary are used to answer those questions in concrete terms.
Concise, trade-focused style for industry readers
Taylor writes in the tight, news-driven style of a specialist trade outlet, assuming readers understand the basics of drug development and are looking for what is new, material and actionable. His pieces are compact, often moving from the topline result to business implications in the opening paragraphs, with methodological detail and secondary data points following in an ordered way.
Quotes are chosen for clarity rather than color. Analyst lines, executive remarks and regulatory details are used to clarify risk, timelines and commercial prospects rather than to add personality. He avoids hype, instead adopting a measured tone that mirrors how cautious investors and development teams talk about probability of success.
Audience focus is evident in the way he balances clinical nuance with business takeaways. Trial acronyms, line-of-therapy distinctions and mechanism-of-action details are included when they change the size of the opportunity, the level of competition or the likelihood of regulatory success. When they do not, they stay in the background, keeping the narrative centered on capital allocation, strategic options and market impact.
Emphasis on reversals, risk and downside
A defining feature of Taylor’s work is his attention to the downside of biopharma, not only the upside. Negative trials, unexpected safety signals and programs that fail to live up to expectations are treated as stories that matter just as much as breakthrough readouts. His Regeneron melanoma coverage leans into disappointment and confusion among analysts and stakeholders, reflecting how reversals reshape pipelines and investor theses.
He often highlights how companies respond to bad news: whether they double down on a mechanism, pivot to narrower indications or de-emphasise an asset altogether. By tracking these responses, he shows how management teams manage risk, communicate with markets and adjust their portfolios when data undercuts prior narratives.
That focus on reversals and risk gives his biopharma business reporting a pragmatic edge. For readers who follow biotech as operators, partners or investors, his stories map the gap between expectations and reality and explain how that gap feeds directly into valuations, deal terms and the future direction of drug pipelines.
4 more business journalists.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex Smith
Alex Smith focuses on the business impact of enterprise technology, with a distinctive emphasis on AI literacy and skills rather than technical specifications. They write for Technology Record, covering how artificial intelligence and cloud platforms from major providers are turned into concrete programmes for organisations and governments. Their beat sits at the junction of business strategy, national digital policy and large-scale technology partnerships. They report on national AI literacy programmes and public–private partnerships, showing how policy choices, vendor capabilities and skills gaps intersect. On the business beat, they treat AI and cloud as tools for competitiveness, workforce readiness and participation in a data-driven economy. Their concise, announcement-led reporting highlights who is partnering with whom, what programme is being launched, which technologies underpin it and how it changes capability on the ground for executive readers.
Alison Durkee
Alison Durkee focuses on how law, regulation and politics create business risks for major companies and industries. She is a reporter at Forbes, where she writes news-driven explainers on complex legal and regulatory developments and their impact on corporate strategy, reputation and markets. Her coverage centers on companies under scrutiny, especially in technology and other high-growth sectors, and tracks trials, investigations and fast-changing policy fights. She breaks down lawsuits, inquiries and regulatory moves into clear parts, grounded in timelines, filings and official actions. She reports on generative artificial intelligence and other emerging technologies as tests of legal frameworks and corporate risk management, explaining how issues like intellectual property, safety compliance, consumer protection and governance can reshape product roadmaps, partnerships and investor expectations.
Alyson Shontell
Alyson Shontell covers business through the lens of leadership, using in-depth conversations with powerful executives and founders to show how their decisions shape companies, markets, and public life. She is editor in chief at Fortune, overseeing coverage across the masthead while continuing to write selected high-impact pieces. Her core work is long, reported interviews and profiles of CEOs of large companies, dominant tech firms, and fast-growing startups. She focuses on how leaders think, manage risk, make unconventional calls, and handle crises, culture, and the future of work. Her subjects include corporate chiefs, startup founders, and political figures treated as executives. She probes operating detail, governance, internal culture, and trade-offs around growth, disruption, and workplace models, using concrete examples and direct, accessible prose that foregrounds the subject’s voice while pressing for specifics.